A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity
Cell Discov
.
2020 Jul 28;6(1):49.
doi: 10.1038/s41421-020-0181-z.
eCollection 2020.
Authors
Adam M Burgoyne
#
1
,
Kendra R Vann
#
2
,
Shweta Joshi
3
,
Guillermo A Morales
4
,
Francisco M Vega
3
5
,
Alok Singh
3
,
Dhananjaya Pal
3
,
Aran B Merati
1
,
Tatiana G Kutateladze
2
,
Donald L Durden
3
4
Affiliations
1
Division of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA USA.
2
Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO USA.
3
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA USA.
4
SignalRx Pharmaceuticals, San Diego, CA USA.
5
Department of Cell Biology, Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Sevilla, Spain.
#
Contributed equally.
PMID:
32793389
PMCID:
PMC7385619
DOI:
10.1038/s41421-020-0181-z
No abstract available
Keywords:
Cancer therapy; Epigenetics; X-ray crystallography.
Grants and funding
R42 CA192656/CA/NCI NIH HHS/United States
R01 GM125195/GM/NIGMS NIH HHS/United States
R01 GM135671/GM/NIGMS NIH HHS/United States
T32 HL086344/HL/NHLBI NIH HHS/United States
R41 CA192656/CA/NCI NIH HHS/United States
R01 HL151334/HL/NHLBI NIH HHS/United States
R01 FD005113/FD/FDA HHS/United States